Moreover, it has been determined that broad-spectrum HDAC inhibitors can synergize with EGFR inhibitors, leading to increased apoptosis in cancer cells and sensitization of resistant cells to EGFR inhibition48,49. This evidence concerns the gene HDAC9 and cancer.